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he 14-3-3 family of eukaryotic proteins are abundant, medium sized proteins (~30 kDa subunit mass) endowed 
with a well-characterized phosphopeptide-binding ability1. his feature allows members of the family to work 
in synergy with several protein kinases, which, upon activation, phosphorylate their client proteins to trigger 
speciic recognition by 14-3-3 proteins. his binding event is a key node in many protein-protein interaction 
networks that regulate a plethora of cellular processes, including apoptosis, cell division, ion channel traicking, 
signal transduction, hormonal production and cytoskeleton rearrangements1–3. Consequently, 14-3-3 proteins 
are major players in a range of human disorders, such as cancer and neurodegenerative diseases, making them 
important targets for drug discovery and therapy.
In all organisms, 14-3-3 proteins are usually present as several isoforms that are encoded by separate genes1. 
he human 14-3-3 family comprises 7 isoforms (β, σ, ζ, γ, τ, ε, η), that form all-helical W-shaped homo- and het-
erodimers4–6. hese proteins function as recognition modules that bind a posttranslationally modiied segment 
of partner proteins and, with rare exceptions7–10, do not interact with non-phosphorylated partners. More spe-
ciically, 14-3-3 s bind protein partners that have phosphorylated serine and/or threonine residues presented in a 
speciic molecular context11. Indeed, 14-3-3 proteins were the irst phosphoserine-binding modules discovered12. 
Pioneering research using peptide libraries established the consensus motifs I and II, RSX[pS/pT]XP and RXY/
FX[pS/pT]XP (X is any amino acid)13, respectively, that preferentially interact with 14-3-3. his immediately sug-
gested that protein kinases with overlapping target sequences (e.g., AGC and CAMK family kinases recognizing 
(R/K)XXS motifs14) might co-operate with 14-3-3, regulating its interaction with target proteins. Later discovery 
of an additional interacting motif III (pS/pTX(X)-COOH), found at the C terminus of several interacting part-
ners, expanded the binding repertoire of 14-3-3 proteins15. he on-going research on 14-3-3 partners is constantly 
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expanding the library of binding sequences16. For example, it became clear that many 14-3-3 partners do not have 
Pro/Gly at position +2, difering from the initially deined consensus. Other signiicantly deviating examples 
include peptides of p53 (LMFKpT387EGPD), histone acetylase-4 (LPLYTSPpS350LPNITLGLP) and peptidylargi-
nine deiminase isoform VI (SSFYPpS446AEG), for which the structural basis for interaction with 14-3-3 has been 
derived by crystallography17–19.
At present more than 2000 potential 14-3-3 interactors have been postulated20, demonstrating involvement of 
14-3-3 members in many cellular mechanisms. Computational tools have been developed for prediction of poten-
tial 14-3-3 binding sites20–22 and calculating binding ainities of each phosphopeptide based on contribution of 
individual amino acids to the binding stability16. he most optimal binding sequence has a positively charged 
Arg/Lys residue at position −3 from the central phospho-residue while a downstream Gly/Pro at position +2 
confers either lexibility or a kink in the peptide conformation necessary for tight interaction in the amphipathic 
groove (AG) of 14-3-313. Remarkably, usually the equivalent non-phosphorylated sequences fail to bind to 14-3-
3, suggesting that ainity is determined predominantly by electrostatic interactions that attract phosphopeptide 
to the AG during an initial stage of binding23. Accordingly, millimolar concentrations of inorganic phosphate or 
sulfate may signiicantly inhibit 14-3-3/phosphotarget interactions by competing for binding at the AG24.
A signiicant inding was that 14-3-3 proteins predominantly interact with proteins enriched with intrinsically 
disordered protein regions25 and that the speciic phosphorylatable 14-3-3 binding sequences are mostly lexi-
ble and disordered. his poses substantial challenges for structural investigation of 14-3-3/partner interactions. 
Indeed, crystal structures are available for only two complexes of 14-3-3 with relatively complete target proteins, 
arylalkylamine N-acetyltransferase (PDB ID 1IB126) and the small heat shock protein HSPB6 (PDB ID 5LTW27). 
Limited structural information prevents understanding of the molecular basis for function of this key regulatory 
node involved in many clinically important signal transduction pathways, decelerating the development of novel 
therapeutic approaches. For example, such information is vital for inding small molecule modulators of speciic 
14-3-3/target complexes28–32 that won’t afect interactions of 14-3-3 with other targets. Ultimately, it would be 
important to screen for such modulators of 14-3-3 complexes with a whole diverse range of peptide sequences, 
including low-ainity peptides mediating transient interactions. In addition, the current lack of structural infor-
mation prevents delineating a universal “14-3-3 binding law” and understanding molecular details of the selec-
tivity for 14-3-3 interaction with hundreds of competing partners.
Structure determination for the 14-3-3/peptide complexes is oten challenged by the low ainity of peptides 
and/or their limited solubility, preventing formation of complexes with fully occupied binding sites. To aid struc-
ture determination, we have developed a streamlined approach based on chimeric 14-3-3 proteins fused to the 
sequences of interacting peptides. Such chimeric proteins are easy to design and allow rapid production of large 
quantities of soluble, crystallization quality protein material. Interacting peptide sequences are fused to the C 
terminus of 14-3-3 through an optimized linker and subsequently phosphorylated during bacterial co-expression 
with protein kinase A, to yield fully phosphorylated material facilitating binding of a fused phosphopeptide in 
the AG of 14-3-3. As proof of principle, we produced chimeras for three diferent phosphopeptides and demon-
strated that it is possible to obtain difraction quality crystals for all of them. his approach provided accurate 
structural information on 14-3-3/peptide complexes, overcoming the limitations of traditional co-crystallization 
approaches with synthetic peptides. Importantly, this approach is compatible with high-throughput studies suita-
ble for the wide 14-3-3 interactome. Furthermore, the approach involving chimeric 14-3-3 proteins can accelerate 
the design of novel biosensors for in vitro screening and in vivo imaging, as well as construction of extended 
protein-protein chimeras involving 14-3-3.

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Ǥ To probe whether the proposed 
14-3-3 chimera proteins fused with diferent phosphopartner peptides would be amenable for crystallographic 
studies, we designed a prototypical chimera based on the available crystal structure of the HSPB6/14-3-3σ com-
plex27. hus, the C terminus of 14-3-3σ was fused to the N terminus of the HSPB6 peptide comprising the key 
Ser16, which is phosphorylated both in vivo and in vitro by cyclic nucleotide-dependent protein kinases A (PKA) 
and G (PKG)33. An easily crystallizable C-terminally truncated mutant of human 14-3-3σ (Clu3 mutant)27 was 
used as the scafold for these chimeras. he length of the peptide linker between the 14-3-3 sequence and the 
phosphopeptide fusion is critical for ensuring interaction. he linker length was informed by structural data on 
the Cryptosporidium parvum 14-3-3, Cp14b protein, where its own C-terminal peptide, phosphorylated during 
expression in E. coli, was bound in one of its AGs (PDB ID 3EFZ)34 (Fig. 1A). Despite the uncommon overall fold 
of this rather exotic 14-3-3 member, it deined a linker of ten residues, between the highly conserved C-terminal 
tryptophan of 14-3-3 (position 0, Fig. 1B) and the anchored phospho-residue (position 10, Fig. 1B) bound in 
the AG. he linker used for fusing the HSPB6 phosphopeptide to the C-terminal of 14-3-3σ∆C included: the 
ordered hr residue at position 1 (Fig. 1B) that is always present in electron density maps, even for C-terminally 
truncated 14-3-3 variants; the natural Leu residue preceding the 14-3-3 binding motif of HSPB6 (RRApS16APL); 
and a GSGS segment designed to provide maximal lexibility to create the prototypical 14-3-3/HSPB6 chimera 
CH1 (Fig. 1B). Additional chimeras of 14-3-3σ∆C were designed to contain peptides from recently described 
physiological, but structurally uncharacterized, 14-3-3 partners, Gli (chimera CH2) and StARD1 (chimera CH3; 
Fig. 1B). he three chimeras CH1-3 were expressed as N-terminal His-tag fusions cleavable by the highly spe-
ciic 3C protease to facilitate their puriication (Fig. 1C). To achieve stoichiometric phosphorylation of peptides 
within the chimeras, we co-expressed them in E. coli with the catalytically active subunit of protein kinase A 
(PKA), known to phosphorylate 14-3-3 binders in vivo33,35,36. Importantly, the 14-3-3σ itself, unlike most of other 
isoforms, is resistant to PKA phosphorylation and subsequent homodimer dissociation37, as it does not contain 
the semi-conservative serine at the subunit interface, which has been reported to destabilize 14-3-3 dimers upon 
phosphorylation5,38.
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his design allows large scale co-expression of soluble phosphorylated 14-3-3 chimeras which can be readily 
puriied by standard chromatographic approaches (Fig. 1D). his procedure generated milligram quantities of 
protein samples that were greater than 98% pure and fully soluble (see Fig. 1E, lane “P”). he properties of the 
prototypical CH1 chimera were analyzed in some detail, prior to structural studies on all three chimeras.
 ? ?Ǧ ?Ǧ ?Ȁ ?Ǧ ?Ǥ CH1 co-expressed 
with PKA (pCH1) resulted in higher mobility during native gel-electrophoresis than for its unphosphorylated 
counterpart (Fig. 1A, inset). Likewise, in vitro phosphorylation of the latter by PKA resulted in increased elec-
trophoretic mobility, whereas further incubation with alkaline phosphatase partly reversed this efect, suggesting 
that it is associated with protein phosphorylation and that CH1 can be phosphorylated by PKA both in vitro and 
inside bacterial cells.
he analytical SEC proile for pCH1 contained a major symmetric peak (peak “I”, representing 85–90% of the 
protein) corresponding to particles with an average hydrodynamic radius RH of 3.4 nm and a minor peak (peak 
“II”) corresponding to particles with the radius of 4.9 nm (Fig. 2A). Comparison with the proiles of a monomeric 
mutant form of 14-3-3ζ (peak at 2.77 nm consistent with previously reported RH value ~2.8 nm39,40) and unphos-
phorylated CH1 (expressed without PKA; single symmetrical peak at 3.6 nm) suggests that peak I of pCH1 cor-
responds to a dimeric form, whereas peak II corresponds to a higher oligomeric form present in much smaller 
quantities (10–15%). he apparent smaller radius of the pCH1 dimer (3.4 nm) compared to the 3.6 nm radius of 
the unphosphorylated protein indicates compaction of the chimera upon phosphopeptide binding. During this 
transformation the C-terminal lobes of the 14-3-3 core are thought to move relative to the N-terminal base of the 
protein, to form a closed state upon peptide binding6,41. he shit in SEC proile is indicative of formation of this 
Figure 1. Design and production of the 14-3-3/phosphopeptide chimeras. (A) – Crystal structure of the 
asymmetrical 14-3-3 from C.parvum (Cp14b) with phosphorylated lexible C terminal peptide (numbered 
residues) bound in the AG of one 14-3-3 subunit (PDB ID 3EFZ). Each subunit is colored by gradient from N 
(blue) to C terminus (red). (B) – Alignment of C-terminal regions of Cp14b and chimeras CH1-CH3 showing 
the linker connecting the conserved Trp (position 0, arrow) of 14-3-3 and the phospho-site (position 10, 
arrow). Linker sequence is in grey font and the phospho-site is in red font. For comparison, 14-3-3 binding 
motif I is shown below the alignment. (C) – Schematic depiction of the 14-3-3/phosphopeptide chimeras. (D) 
– Puriication scheme for obtaining crystallization-ready CH proteins phosphorylated in the course of bacterial 
co-expression with His-tagged PKA, including subtractive immobilized metal-ainity chromatography (IMAC) 
for the N-terminal hexahistidine tag removal by 3C protease and size-exclusion chromatography (SEC). (E) 
– Electrophoretic analysis of fractions obtained during IMAC1 and IMAC2 for CH1 (IMAC1) or CH1-CH3 
(IMAC2). Lanes are labeled as follows: (L) – loaded fraction, (F) – lowthrough (10 mM imidazole), (W) – wash 
(10 mM imidazole), E1 – elution at 510 mM imidazole during IMAC1, E2 – elution at 510 mM imidazole during 
IMAC2. Note the shit of chimera bands as a result of tag removal by 3C (+/− H6). Flow through fractions 
(F) during IMAC2 (red circles) were subjected to additional SEC puriication (P – inal sample) prior to 
crystallization.
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closed or phosphopeptide ‘bound’ state. We can speculate that the small fraction of the larger particles with the 
4.9 nm radius is likely due to the concentration dependent cross dimer patching of one chimeric phosphopeptide 
to another chimeric 14-3-3 dimer to form tetramers (see below).
To further characterize the conformation change between unbound and bound states of the CH1 chimera, 
we used diferential scanning luorimetry42. We compared CH1 chimera with the unphosphorylated control and 
the core 14-3-3σ∆C dimer (Fig. 2B). In this experiment, unphosphorylated CH1 and 14-3-3σ∆C underwent 
main thermally-induced transitions with half-transition temperatures of 61 and 65 °C, respectively (Fig. 2B, cyan 
and blue curves). Under identical conditions, the half-transition temperature for pCH1 was ~70 °C, i.e. 5 or 10° 
higher, indicating enhanced protein stabilization. his is most likely a result of the phosphopeptide binding into 
the AG and the resulting overall compaction indicated by SEC. Importantly, lowering the pCH1 concentration to 
1 µM did not result in any signiicant destabilization, indicative of a strong phosphopeptide binding even at low 
protein concentrations (Fig. 2B). In contrast, addition of equimolar concentrations of untethered phosphopeptide 
with protein at 1 µM would have resulted in ≤12% of the AG occupancy (given the apparent KD of 6.3 ± 0.5 µM27). 
he apparent increase in binding ainity due to co-localization through fusion with 14-3-3 is highly advanta-
geous for future utilization of 14-3-3 chimeras in biosensor technology, which normally involves low protein 
concentrations.
 ?Ǥ he pCH1 chimera crystallizes under a variety 
of conditions in several diferent crystal forms (Table 1). hus, unlike the natural disordered C-terminal segment 
of 14-3-3, the phosphopeptide fusion per se does not hamper crystallization. One can expect that derivatives of 
pCH1 with other phosphopeptides will crystallize equally well.
Two crystal forms of the pCH1 chimera are remarkably distinct difering by the relative orientation and pack-
ing of 14-3-3 dimers in the crystal (Fig. 3). In one crystal form (pCH1℧, Table 1), the C-terminal lobes of each 
of the two subunits within a 14-3-3σ dimer are in contact with one C-terminal lobe in each of the two adjacent 
dimers (Fig. 3A). hey form an interface along the length of the α-helix 9 of 14-3-3 stabilized by contacts between 
pairs of residues Tyr213/Tyr213′ and Gln221/Gln221′. As expected, the chimeric protein CH1 co-produced in 
bacteria with PKA was speciically phosphorylated at the authentic Ser residue (Ser16 of HSPB633). In the struc-
ture, pairs of subunits belonging to two diferent 14-3-3 dimers are linked by a reciprocal interdimer phospho-
peptide swap, in the course of which phosphopeptides, fused to the C-terminus of each subunit, cross-patch into 
the AG of the adjacent monomer. he electron density maps, calculated at 2.35 Å resolution (Fig. 3B and Table 2), 
allow unambiguous tracing of amino acids for a complete C terminus of the pCH1 chimera, including all residues 
of the linker with the exception of leucine at position +3 relative to pSer16. Lying just outside the primary 14-3-3 
binding motif, RXXpSXP, this residue has no clear electron density suggesting its conformational variability. 
Notably, although being very short, the GSGS linker was long enough to allow phosphopeptide binding to the 
14-3-3 monomer of an adjacent dimer.
Importantly, irrespective of the interdimer peptide swap, the phosphopeptide orientation and conforma-
tion were identical to that of the synthetic HSPB6 peptide co-crystallized with the 14-3-3σ (PDB ID 5LU1 and 
5LU227), with the Cα r.m.s.d. of 0.23 Å for the residue segment RRApSAP (Fig. 3C), indicating highly speciic 
binding and absence of any signiicant steric hindrance caused by peptide fusion. Consistent with available 
14-3-3/peptide crystal structures, in the pCH1℧ structure reported here, the phosphate moiety of the peptide 
Figure 2. pCH1 characterization. (A) – Analytical SEC proiles of the monomeric mutant of 14-3-3ζ and 
the 14-3-3σ fusion with HSPB6 phosphopeptide expressed in the absence (CH1) or in the presence (pCH1) 
of PKA, obtained using a calibrated Superdex 200 10/300 Increase column (GE Healthcare). Elution proiles 
were followed at 280 nm and normalized to absorbance at the peak maxima. Average hydrodynamic radii 
corresponding to peak maxima obtained from column calibration are indicated. Peaks I and II of the CH1 
proile are marked. Inset shows the migration of CH1 (1), CH1 co-expressed (2) or in vitro phosphorylated (3) 
by PKA, or pCH1 in vitro dephosphorylated by alkaline phosphatase (4) during native gel-electrophoresis. (B) 
– Heating of 14-3-3σ∆C (1.5 µM), unphosphorylated CH1 (5 µM) or phosphorylated CH1 (1–5 µM) samples 
from 10 to 80 °C at a constant rate of 1 °C/min followed by intrinsic tryptophan luorescence (direction is shown 
by arrow) and analyzed by plotting fraction of unfolded protein versus temperature (See Methods).
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Chimera 14-3-3σ Clu3 – HSPB6 phosphopeptide* 14-3-3σ Clu3 – Gli1 phosphopeptide** 14-3-3σ Clu3 – StARD1 phosphopeptide**
Topology bi-directional peptide swap self-bound mono-directional peptide swap bi-directional peptide swap
Designation pCH1℧ pCH1X pCH2 pCH3
Crystallization 
solution (reservoir)
0.1 M MMT (malate-MES-
Tris) pH 4, 25% PEG 1500
0.1 M Na-acetate pH 4.6, 
20 mM CaCl2, 30% MPD
0.1 M HEPES pH 7.5, 1 M 
Na-acetate, 50 mM CdSO4
0.1 M bis-Tris (pH 6.5), 2 M (NH4)2SO4
0.1 M bis-Tris-propane pH 6.5, 
0.2 M (NH4)2SO4, 25% PEG 3350
Crystal handling no cryosolution
no cryosolution 
(crystallization solution 
contained 30% MPD)
no cryosolution
cryosolution: 20 mM Tris pH 7.5, 0.1 M 
bis-Tris pH 6.5, 2.4 M (NH4)2SO4, 
150 mM NaCl, 20% glycerol
no cryosolution
Resolution, Å 2.35 2.5–3.3 3.2 3.2 3.9
Protein conc. (mg/ml) 23 23 (seeding) 23 20.6 10.1
Temperature (°C) 20 20 20 20 20
Growth time (days) 8–12 1–4 3–6 8–14 7–10
Table 1. Crystallization conditions. Prior to crystallization, protein samples were additionally puriied 
by SEC in 25 mM Tris pH 7.0–7.5 with 150 mM NaCl and with either 1 mM dithiothreitol (*) or 
3 mM β-mercaptoethanol (**). PEG – polyethylene glycol; MPD – 2-Methyl-2,4-pentanediol; MES – 
2-(N-morpholino)ethanesulfonic acid; Tris – tris(hydroxymethyl)aminomethane.
Figure 3. Crystal structures of the pCH1 chimeric protein. (A) – molecular packing in the pCH1℧ crystal 
form with the phosphopeptide (red sphere) swap between monomers of two 14-3-3 dimers. 14-3-3 subunits 
are shown as colored ribbons forming an inverted Ω shape; one physiological 14-3-3 dimer is highlighted 
by a semitransparent surface. (B) – magniied view showing the linker and the phosphopeptide with the 
corresponding 2Fo-Fc electron density contoured at 1σ (residues are labeled, with numbers indicating positions 
with respect to pSer). (C) – Comparison of phosphopeptide conformations in the pCH1 (this work) and 5LU1 
(synthetic HSPB6 phosphopeptide co-crystallized with 14-3-3σ27) structures. (D) – molecular packing in the 
pCH1X crystal form with no peptide swap (dashed lines correspond to unresolved parts of the linker).
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forms salt bridging interactions with the conserved 14-3-3σ residues Lys49, Arg56, and Arg129 and a hydrogen 
bond with Tyr130 (Fig. 3B). he main-chain atoms of alanines immediately adjacent to the phosphoserine make 
hydrogen bonding interactions with 14-3-3 residues Asn226 and Asn175, as observed in the 5LU1 structure27. 
his suggests that the proposed chimeric proteins can in principle be used to gain structural insights into the 
14-3-3 interaction with any potential phosphopartners. Fusing phosphopeptides to the 14-3-3 protein imposes a 
1:1 molar ratio for the two interacting moieties, eliminating the need to synthesize peptides and to optimize their 
concentration for achieving high occupancy while ensuring production of difraction quality crystals.
he equivalence of protein-peptide interactions in fusion constructs was conirmed by the second crystal form 
of pCH1, where in the ASU we found two 14-3-3σ dimers located “back-to-back” (pCH1X, Fig. 3D and Table 2). 
In this case, the fused phosphopeptides appear to be bound back into the AG of the same monomer, resulting in 
fully occupied AGs. Notwithstanding the lower resolution of the corresponding crystal structure (3.2 Å), most of 
the phosphopeptide residues and several linker residues were resolved in electron density maps, yielding essen-
tially the same structure of the bound phosphopeptide as for the pCH1℧ crystal form.
Crystal structures of the pCH1 chimera supported conclusions drawn from SEC data. Hydrodynamics calcu-
lations by HydroPro43 using the crystallographic pCH1 dimer (Fig. 3D) or dimer of dimers stabilized by recip-
rocal interdimer phosphopeptide links (Fig. 3A) resulted in RH values 34.6 and 49.8 Å, respectively, in excellent 
agreement with the SEC-derived values of 3.4 nm and 4.9 nm (Fig. 2A).
 ? ?Ǥ Having found that the prototypic chimera pCH1 was 
structurally equivalent to 14-3-3 complex with synthetic phosphopeptide (Fig. 1D), but superior for complex 
preparation and crystallization, we created two further 14-3-3 chimeras, pCH2 and pCH3, containing structur-
ally uncharacterized phosphopeptide binding partners in an attempt to obtain the irst structural information for 
these complexes.
PKA-dependent phosphorylation and subsequent interaction of the transcription factor Gli, a central player 
in Hedgehog signaling35, and the steroidogenic acute regulatory protein StARD136,44 with 14-3-3 proteins have 
recently been reported, however, no accurate structural information on these complexes was available. he pro-
posed 14-3-3 binding phosphopeptide RRAS640DPAQA is conserved in all Gli proteins, i.e Gli1, Gli2 and Gli3. 
StARD1 has two phosphopeptide motifs, RRSS57LLGS and RRGS195TCVL that are expected to interact with 
14-3-3. For chimeric protein construction, we have chosen the main phospho-site of Gli for pCH2 and the irst 
potential 14-3-3 binding motif of StARD1 (RRSS57LLGS) for pCH3. A similar phosphopeptide motif to StARD1 
is found at Ser87 position of human Bcl-2-like protein 11 (BimEL11). CH2 and CH3 proteins were co-expressed 
with PKA and puriied in a fully soluble form using the same protocol as for pCH1 (Fig. 1), indicating that the 
high inherent solubility of 14-3-3 is not compromised by peptide addition at its C terminus. Both proteins readily 
crystallized in various conditions producing difraction-quality crystals of diferent morphologies straight out of 
commercial screens (see Table 1).
pCH1℧ pCH1X pCH2 pCH3
Data collection
Space group P 1 21 1 P 21 21 21 P 64 2 2 P 41 21 2
Cell dimensions: a, b, c (Å) 63.6, 140.6, 68.7 77.4, 97.8, 158.8 110.4, 110.4, 174.1 123.3, 123.3, 162.4
α, β, γ (°) 90, 114.8, 90 90, 90, 90 90, 90, 120 90, 90, 90
Resolution range (Å)* 47–2.35  [47–6.6]  (2.51–2.35) 46.5–3.2  [46.5–6.9]  (3.31–3.20) 48–3.2  [48–9.4]  (3.38–3.19) 49–3.9  [49–11.4]  (4.12–3.89)
Wavelength (Å) 0.9795 0.9795 0.9795 0.9282
Rmerge** 0.19 [0.07] (1.2) 0.45 [0.08] (3.1) 0.23 [0.03] (4.3) 0.30 [0.06] (2.9)
Rmeas 0.20 [0.08] (1.4) 0.49 [0.08] (3.4) 0.23 [0.03] (4.4) 0.30 [0.06] (3.1)
<I/σ> 6.5 (1.2) 4.4 (0.7) 14.3 (0.9) 6.8 (1.0)
CC1/2 0.99 (0.5) 0.99 (0.3) 1.00 (0.5) 1.00 (0.3)
Completeness (%) 95.5 (84.6) 99.8 (99.9) 99.6 (98.2) 99.6 (98.4)
Redundancy 3.9 (3.8) 6.5 (6.7) 23.0 (22.3) 12.8 (12.7)
Reinement
No. of relections: total 43838 20548 10910 12947
‘free’ set 1385 1016 977 1049
Rwork(%) 19.1 24.7 21.5 20.9
Rfree (%) 24.0 27.9 26.7 24.8
No. of 2:2 complexes/asu 2 2 1 2
No. of non-H atoms: protein/ligands/
solvent 8071/35/493 7327/17/22 3655/40/7 7246/38/1
R.m.s.d. bond lengths (Å)/angles (°) 0.010/1.0 0.010/1.0 0.010/1.1 0.010/1.1
Ramachandran favoured/outliers (%) 97.7/0.1 98.1/0.1 96.0/0.4 96/0.6
Molprobity score/Clash score 1.3/0.99 1.6/1.05 1.9/2.07 2.1/3.04
PDB code 5OK9 5OKF 5OM0 5OMA
Table 2. X-ray data collection and reinement statistics. *Statistics for the lowest and highest resolution shells 
are indicated in square brackets and parentheses, respectively. **All statistics as deined in XSCALE54.
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he pCH2 crystal structure was determined at 3.2 Å resolution (Table 2). here is one 14-3-3 dimer per asym-
metric unit; forming a closed cyclic structure with its symmetry mate where a single subunit of each dimer con-
tributes its phosphopeptide to the binding site of the closest subunit of an adjacent dimer (Fig. 4A) having its own 
binding site occupied by a sulfate ion (sulfate was present in crystallization condition). In the inter-dimer com-
plex, the central Ser640 is bound by the same canonical residues of AG as in pCH1 (Fig. 3B) and other 14-3-3/
phosphopeptide complexes. Interestingly, this binding mode leaves the two opposite AGs unoccupied by the two 
remaining phosphopeptides which are unresolved in electron density maps. Instead, these ‘unbound’ AGs appear 
to be occupied by sulfate anions present in crystallization media at high concentration (Fig. 4A and Table 1). One 
can speculate that the very high sulfate concentration (2M) may have forced the phosphopeptides to partially 
dissociate from the AG facilitating this distinct crystal packing, in line with the inhibitory efect of phosphate 
and sulfate ions on 14-3-3/phosphotarget interactions observed in vitro24. he quality of electron density maps 
allowed unequivocal tracing of all linker residues of the Gli-derived phosphopeptide, except for the C-terminal 
alanine (Fig. 4B). Interestingly, two closely packed phosphopeptide-binding 14-3-3 subunits belonging to two 
diferent dimers, form Cys38-Cys38 disulide bridge. However, this interaction is distant to AGs of each subunit 
and does not appear to interfere with 14-3-3/phosphopeptide interactions. his example demonstrates that the 
14-3-3/phosphopeptide fusions are useful for producing accurate structural information for 14-3-3 complexes 
with partners for which little or no information on binding ainity is available.
Unexpectedly, structural data obtained for the pCH3 chimera were signiicantly diferent. Most crystals pro-
duced poor difraction, with the best 3.9 Å resolution data set collected from a crystal with two trans-interacting 
Figure 4. Crystal structures of pCH2 and pCH3 chimeric proteins. (A) – crystal packing of two adjacent 
dimers of the 14-3-3σ fusion with Gli phosphopeptide (pCH2), showing phosphopeptide exchange between the 
two dimers. A close-up view at the sulfate anion (orange) bound in the peptide-free AG of the phosphopeptide 
donor subunit (inset). (B) – Close-up view at the bound Gli phosphopeptide with 2Fo-Fc maps contoured at 
1σ and with indicated key residues. (C) – packing of two dimers of the 14-3-3σ fusion with StARD1/BimEL 
phosphopeptide (pCH3 chimeric protein). he phosphorylated linker GSGpSLRR, the sulfate anion and the 
unresolved phosphopeptide (indicated by labeled arrows) are shown with corresponding 2Fo-Fc electron 
density maps contoured at 1σ. (D) – overlay of 14-3-3 dimers obtained by superposition of a single subunit, 
demonstrating conformational diferences between the fully closed and open states, with up to ~16 Å positional 
diferences.
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dimers in the ASU (Fig. 4C and Table 2). he electron density maps of two neighboring subunits belonging to two 
diferent 14-3-3 dimers were clear enough to trace the C-terminal portion and the following peptide and to con-
clude that it binds in the AG of the adjacent subunit. Although the distance between the C-terminal tryptophan 
of the 14-3-3 core and the positively charged residues typically coordinating the phosphoserine, was too short 
to allow canonical phosphopeptide binding, binding of a phosphorylated residue was still observed (Fig. 4C). 
Surprisingly, in both cross-patching peptides, we found that it was the second Ser residue of the linker (-GSGpS-) 
that was phosphorylated and bound in the adjacent subunits’ AG (Fig. 4C). In one of the chains, we could trace 
three residues beyond this pSer, LRR, indicating that the bound peptide had a completely reversed orientation to 
those observed for pCH1, pCH2 and other known 14-3-3/phosphopeptide structures. his clearly exempliied 
the extremely rare case when a peptide phosphorylated by PKA at a non-canonical position (N-..pSXXR..-C 
instead of N-..RXXpS..-C) was then erroneously accommodated in the AG of 14-3-3 but in the non-standard, 
opposite orientation. his could be an artifact caused by a relatively high level of PKA co-expression, reducing 
phosphorylation speciicity, although under the same conditions this did not happen to pCH1 and pCH2, where 
the same linker remained unphosphorylated. We note that an atypical reversed orientation of the peptide frag-
ment in the AG of 14-3-3ζ has been previously reported for the Exoenzyme S (PDB ID 2O02). We do not know 
the phosphorylation status of the target and neighboring serine residues (RRSSLLGSR, underlined), however, 
to exclude atypical phosphorylation, serine residues in the GSGS linker could be avoided. Although it was not 
possible to observe the canonically bound conformation of the StARD1/BimEL phosphopeptide, this remarkable 
crystal structure illustrates the promiscuity of the 14-3-3 groove, exemplifying multiple exceptions to the estab-
lished canonical binding rules based on motifs I-III13,15. his example further demonstrates the value of 14-3-3 
chimeras for structural studies of weakly binding phosphopeptides which difer signiicantly from the canonical 
higher ainity motifs.
Interestingly, in the pCH3 structure, both 14-3-3 dimers adopted a signiicantly more open overall conforma-
tion than in the pCH1 or pCH2 cases (Fig. 4D). Superposition of one of the 14-3-3 dimer monomers showed that 
the extreme position of the C-terminal α-helix of the second monomer difered by up to 16 Å (dimer 1 of pCH3 
had an intermediate position), reminiscent of the quite unique structure of the apo-14-3-3β isoform with one 
subunit in a closed and one in an open conformation6. Surprisingly, in the pCH3 structure, the open conforma-
tion of the 14-3-3σ subunit did not prevent binding of either the sulfate ion or a phosphorylated peptide (Fig. 4C, 
yellow). Accurate structural data on diferent 14-3-3 conformations support earlier predictions by molecular 
dynamics41.

Progress in translating the wealth of available knowledge on 14-3-3 proteins into novel therapeutic approaches 
is oten limited by the lack of accurate structural information on speciic complexes of these hub proteins with 
interacting partners. We attempted to resolve this problem by designing chimeric proteins where the phospho-
peptide binding partner is fused to a 14-3-3 core. We probed whether such chimeric proteins are soluble and 
whether they are suitable for structural studies by protein crystallography. Our data demonstrate that chimeras 
can be used for setting up a streamlined and highly eicient protein crystallization pipeline for rapid generation 
of structural information for previously uncharacterized 14-3-3 target phosphopeptides, opening up new per-
spectives in 14-3-3 research.
One of the advantages of using the 14-3-3/phosphopeptide chimeras is that they are easy to design and 
produce in a soluble form in E. coli, as solubility is conferred by the highly soluble 14-3-3 protein and phos-
phorylation is achieved by co-expression with a protein kinase. PKA, used in this work for co-expression, may 
be substituted by the cognate kinase known to phosphorylate the target 14-3-3 binding site, provided that it is 
sub-cloned into a compatible expression vector and is soluble in E. coli. Alternatively, in vitro phosphorylation of 
puriied 14-3-3 chimeras (see Fig. 1A, inset) by commercially available protein kinase(s) is also an option.
he established puriication protocol is afordable and straightforward leading to production of large amounts 
(>10 mg per liter of culture) of highly pure (>98%) and monodispersed protein suitable for subsequent crystalli-
zation experiments. he presence of the core 14-3-3 construct optimized for crystallization facilitates production 
of difraction quality crystals, straight from commercial screens. Additionally, chimera/peptide libraries can be 
easily created, since the peptide-encoding DNA can be readily inserted into the chimera expression system using 
synthetic oligonucleotides and current molecular biology protocols. hese advantages make the approach adapt-
able for high-throughput studies, such as screening for novel 14-3-3 protein interacting partners, validation of 
newly identiied protein-protein interactions involving 14-3-3, and screening for small molecule modulators of 
the established 14-3-3/phosphotarget complexes.
he inevitable substantial advantage of the proposed chimeric 14-3-3/phosphopeptide constructs is that the 
covalent tethering ensures 1:1 stoichiometry. In contrast, traditionally utilized synthetic peptides can be labile 
and/or of limited solubility27 and hence crystallization may be inhibited by a large excess of a peptide while too 
little peptide may result in partial occupancy of the AG of 14-3-3. his is especially important for weak binding 
peptides where the apparent decrease in dissociation constant, due to the signiicant increase in local phospho-
peptide concentration when fused to 14-3-3, can assist in obtaining a high binding occupancy of the partner AG 
site. Fusion of such peptides to 14-3-3 with the help of a carefully designed linker presents a unique opportunity 
to obtain corresponding structural information about their conformation in the AG of 14-3-3.
he optimal linker length, oten an Achilles’ heel in fusion proteins, was based on the crystal structure of the 
exotic 14-3-3 protein Cp14b, bound to its own phosphorylated C terminus (Fig. 1A). he approach led to the suc-
cessful structure determination for several 14-3-3/phosphopeptide complexes (Figs 3 and 4). Although the struc-
ture of a 14-3-3ζ chimera with a pseudophosphorylated peptide (S → E substitution) from the tumour suppressor 
LKB1 was reported recently (PDB ID 4ZDR), the mutation or non-optimal (longer) linker resulted in a surprising 
and most likely unspeciic binding of a peptide, manifested by diferent binding to each of the two subunits of the 
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14-3-3 dimer present in the asymmetric unit45,46. Surprisingly, the primary binding site in the 4ZDR structure is 
occupied by a sulfate anion, suggesting that the S → E mutation is a poor mimic of phosphorylation. hus, the 
observed peptide conformation45 cannot be considered as genuine. In contrast, phosphopeptide conformations 
observed for the pCH1 chimera structures reported here were validated by direct comparison with the structure 
of 14-3-3σ complex with synthetic HSPB6 phosphopeptide (PDB ID 5LU1). he comparison showed that the two 
diferent approaches provided almost identical structural information (Fig. 3C), with the Cα r.m.s.d. of 0.23 Å for 
bound peptides.
Interestingly, phosphopeptide binding within the pCH1 chimera resulted in protein compaction and a signif-
icant increase in thermal stability, as evidenced by analytical SEC and luorescence spectroscopy (Fig. 2), in line 
with partial stabilization of 14-3-3 by phosphate and phosphopeptides observed earlier47. Such observations can 
be used to probe the folding and stability of other 14-3-3 chimeras prior to crystallization and may be also useful 
for screening for small molecule inhibitors of 14-3-3/partner interaction.
he approach based on the 14-3-3 chimera scafold, that we introduced here (Fig. 1), can facilitate struc-
tural studies of more complicated 14-3-3 complexes, particularly those where binding partners have a single 
14-3-3-binding site located at their N terminus. For example, ternary complexes involving 14-3-3 scafolds, long 
hypothesized but poorly evidenced so far, could now be studied with increased conidence. One possibility would 
be to use heterodimeric chimeras created through fusion of two diferent phosphopartner peptides to diferent 
14-3-3 isoforms known to preferentially heterodimerize4–6. For other assemblies, where binding of a protein or 
domain to 14-3-3 is only possible ater phosphopeptide binding, 14-3-3 chimeras could be used as preformed 
binding partners. Examples include the ternary 14-3-3 complex, GF14c/OsfD1/Hd3a, that regulates lowering 
in plants48 or the mammalian 14-3-3/HSPB6 regulatory complex, where binding of the alpha-crystallin domain 
of HSPB6 most likely takes place ater 14-3-3/phosphopeptide binding in the AG27. he modular principle of the 
chimeras described in this study could also be adaptable to study phosphoserine/threonine binding proteins more 
generally49.
In summary, we present a simple but powerful approach for rapid production of accurate X-ray structures for 
14-3-3 proteins bound to partner phosphopeptides. We tested this approach by determining structures of 14-3-3/
phosphopeptide complexes and present structural information for novel phosphopeptide complexes of 14-3-3. 
he data provided by these and future structures, produced using this approach, will deepen our understanding 
of the factors dictating phosphopeptide target selection by 14-3-3 proteins, informing the potential development 
of new therapies based on targeting speciic protein interactions.

ǡƤ ? ?Ǧ ?Ǧ ?Ǥ Cloning, overexpression and puriication of 
the monomeric mutant form of human 14-3-3ζ (14-3-3ζm: 12LAE14 → 12QQR14 14) and the untagged C-terminally 
truncated human 14-3-3σ (14-3-3σ∆C: residues 1-231) were described previously27,39,40. To facilitate crystalli-
zation of the protein, we followed the so-called surface-entropy reduction (SER) approach50 and cloned 14-3-
3σ∆C mutant Clu3 with 75EEK77 → 75AAA77 amino acid replacements into a modiied pET28 vector containing a 
3C-cleavable N-terminal hexahistidine tag27. cDNA of the 14-3-3 chimera with the HSPB6 peptide RRAS16APL 
(CH1) was obtained in one PCR step using the pET28-his-3C_14-3-3σ∆C-Clu3 construct as a template by 
high-idelity Pfu polymerase using T7-forward 5′-GACTCACTATAGGGAGACC-3′ and an excess of Clu3-B6p 
reverse p ri mer 5 ′-ATATCTCGAGTCACAACGGGGCGCTAGCGCGGCGCAGGGATCCCGATCCCGTCCAC
AGTGTCAG-3′ introducing the HSPB6 peptide and linker (GSGS) sequences, and XhoI site. cDNA of the 14-3-3 
chimeras with the Gli (CH2) or StARD1/BimEL (CH3) peptides were obtained on the basis of CH1 by the same 
procedure as for CH1 but using 5′-ATATCTCGAGTCATGCTTGAGCAGGATCACTAGCGCGGCGCAG-3′ 
or 5′-ATATCTCGAGTCAACGAGATCCCAGCAGGCTGCTGCGGCGCAGGGATC-3′ reverse primers, 
respectively, introducing the peptide and linker sequences and XhoI site. cDNA of CH1-CH3 was subsequently 
cloned into pET28-his-3C vector using NdeI and XhoI sites for restriction endonucleases and T4 DNA-ligase 
(SibEnzyme; www.sibenzyme.com). Correctness of all constructs was veriied by DNA sequencing in Evrogen 
(www.evrogen.com). he plasmid encoding the CH1 chimera created in this study is deposited with Addgene 
(www.addgene.org) under the accession number 100093. Other plasmids are available from the corresponding 
author on reasonable request.
All phosphorylated chimeras (pCH1-pCH3) were obtained according to the identical scheme. Corresponding 
constructions in pET28-his-3C vector (kanamycin resistance) were used for co-transformation and co-expression 
in E. coli with a His-tagged catalytically active subunit of mouse PKA cloned in pACYC vector (chloramphenicol 
resistance)27 under selection on both antibiotics. CH1 was also obtained in an unphosphorylated state, i.e. via 
expression in the absence of PKA. Protein overexpression in 1 L of Luria-Bertani media was induced at OD600 of 
0.6 by addition of isopropyl-β-D-thiogalactoside to a inal concentration of 0.5 mM for 20 h at 30 °C.
Purification was performed using subtractive immobilized metal-affinity chromatography (IMAC) and 
gel-iltration essentially as described27. Between IMAC1 and IMAC2 steps (loading/washing bufer (A): 20 mM 
Tris pH 8.0, 300 mM NaCl, 10 mM imidazole; elution bufer (B): bufer A with additional 500 mM imidazole) the 
chimeras were dialyzed to remove imidazole and simultaneously cleaved with 3C protease27,51 (1:1000 weight 3C: 
chimera ratio estimated by absorbance at 280 nm) resulting in target proteins with three extra residues GPH- at 
their N terminus. he inal polishing size-exclusion chromatography step was immediately followed by screening 
for crystallization conditions or in vitro characterization. he amount of protein obtained from 1L of bacterial 
culture was usually enough to setup exhaustive initial screening and obtain difraction quality crystals without 
further optimization. All inal protein samples were homogenous according to a Coomassie-stained SDS-PAGE. 
Protein concentration was determined spectrophotometrically at 280 nm.
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ǦǤ Phosphorylation and dephosphorylation of CH1 in vitro were performed as 
described elsewhere37. he results were analyzed by 15% polyacrylamide gel-electrophoresis at pH 8.6 under 
non-denaturing conditions.
ǦǤ he oligomeric status and hydrodynamic properties of 
14-3-3ζm and CH1 or pCH1 were assessed and compared using analytical SEC, as described previously52. 100 µL 
protein samples were pre-incubated for 30 min at room temperature and then loaded on a Superdex 200 Increase 
10/300 column (GE Healthcare) equilibrated with a 20 mM Tris-HCl bufer, pH 7.6, containing 150 mM NaCl, 
0.1 mM EDTA, and 3 mM β-mercaptoethanol (ME), at a low rate of 1.2 mL/min, while monitoring absorbance 
at 280 nm. he column was calibrated with protein standards with known hydrodynamic radii that were used to 
determine average radii RH of the species under study52,53. Proiles were built using Origin 9.0 Pro sotware.
	Ǥ To get insight into thermal stability of proteins, we monitored changes in the 
intensity of intrinsic tryptophan luorescence at 320 (I320) and 365 (I365) nm upon excitation at 297 nm (slits width 
5 nm) during heating of the samples (1–5 µM protein concentration on a 20 mM Hepes bufer, pH 7.1, 150 mM 
NaCl, 0.1 mM EDTA, 2 mM ME) from 10 to 80 °C at a constant rate of 1 °C/min in a temperature-controlled mul-
ticell holder of a Cary Eclipse luorescence spectrophotometer (Varian Inc.). Before the experiment, the samples 
were equilibrated for 10 min at the initial temperature (10 °C). he ratio of I320(T)/I365(T) normalized from 0 to 
100% represented the dependence of completeness of thermal transition, of an unfolded fraction, on temperature 
and was used to estimate half-transition temperatures42. When possible, the single wavelength was used to build 
analogous transition curves53. Graphs were built using Origin 9.0 Pro sotware.
ǦǤ he 14-3-3 chimeras were subjected to crystallization tri-
als immediately ater puriication using commercial screens PACT, Procomplex (Qiagen), Index, Crystal Screen 
(Hampton Research) and JCSG + (Molecular Dimensions). Sitting drops containing 200 nl protein at 10–23 mg/
ml concentration (See Table 1) and 100–200 nl precipitant solution were set up in 96-well plates using the 
Mosquito robot (TTL Labtec). Crystals were diicult to optimize, however, in some cases random matrix micro-
seeding appeared helpful (Table 1). Crystallization plates were incubated at 20 °C and monitored using a Rigaku 
plate imager equipped with a Vis/UV-scanning and detection system.
X-ray difraction data (Table 2) on small crystals, grown directly in 96-well plates, were collected at 100 K 
at beamlines I02 and I04 of Diamond Light Source (UK) using Dectris PILATUS 6MF detectors. Crystals were 
mounted in nylon loops and quickly cooled in liquid nitrogen, predominantly without addition of a cryoprotect-
ant (See Table 1 for details).
ƤǤ Difraction data were integrated and scaled using XDS/
Xscale54 and xdsme55. Phasing of the pCH1-pCH3 was accomplished by molecular replacement with MolRep56 
using the dimer of the 14-3-3σ Clu3 mutant from the PDB ID 5LU1 as a search model. Initial phasing attempts 
in the case of the pCH3 using the 14-3-3σ dimer failed. However, it was possible to solve the structure using the 
14-3-3σ monomer as a search model, with molecular replacement placing three out of four subunits in the ASU, 
and with the fourth subunit that had a substantially diferent (more open) overall conformation recovered in 
Coot57 by manual placing of α-helices into electron density maps calculated with phases based on the three initial 
14-3-3 monomers. he missing C-terminal segments containing fused phosphopeptides and sulfate anions were 
manually built into diference electron density maps. Automated reinement in Buster 2.10.358 initially included a 
rigid-body reinement of all chains and then an all-atom and individual B-factor restrained reinement. Statistics 
of inal reined models are in Table 2. he relatively high R-factors in the case of the pCH1X structure can be 
caused by a pronounced translational NCS detected for this crystal form, which signiicantly complicated the 
reinement. In this case, Zanuda59 was used to validate the P 21 21 21 space group.
All igures depicting the structure were prepared using Pymol 1.6.9 (Schrödinger). Atomic coordinates and 
structure factors have been deposited with the PDB under accession codes indicated in Table 2. All other data 
generated during the current study are included in this article.
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